Medical Tidbits, FDA Approves Medtronic Deep Brain Stimulation for People with Parkinson’s Disease with Recent Onset of Motor Complications

microscopie in lab https://www.medcareernews.commicroscope in medical laboratory

Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of Medtronic Deep Brain Stimulation (DBS) Therapy for use in people with Parkinson’s disease of at least four years duration and with recent onset of motor complications, or motor complications of longer-standing duration that are not adequately controlled with medication. In 2002, the FDA initially approved Medtronic DBS Therapy for use in patients with advanced Parkinson’s disease. Medtronic DBS has demonstrated improvement in motor complications, quality of life, activities of daily living and reduction in medication usage in individuals with Parkinson’s disease.1

Motor complications caused by the disease and/or as a side effect of levodopa result in great social and psychological disability.2 Interference with activities of daily living is often severe and the cost of treatment and care increases along with deterioration of quality of life for patients and their caregivers.2 Thirty-seven percent of people with Parkinson’s retire earlier than those without the disease, retiring an average of six years earlier because of the disease.3 The economic impact of Parkinson’s disease is at least $14.4 billion a year in the United States and it is estimated that the prevalence of the disease will more than double in the United States by the year 2040.4 read more

SAB Biotherapeutics Produces New Human Antibody Treatment for MERS-CoV

SIOUX FALLS, S.D.–(BUSINESS WIRE)–SAB Biotherapeutics, Inc. (SAB), a leading biopharmaceutical development company, announced today it has produced a new human antibody therapeutic to treat the deadly Middle East respiratory syndrome coronavirus (MERS-CoV) utilizing its novel DiversitAb™ production platform. MERS-CoV was first identified in Saudi Arabia in 2012; the World Health Organization has identified it as a “threat to global health.” read more

Replicor to Present Pre-Clinical and Updated Clinical Data on REP 2139-Ca Based Combination Therapy in Chronic HBV and HBV / HDV Co-Infection at APASL 2016

NEW YORK–(BUSINESS WIRE)–Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus (HDV) co-infection, will present preclinical and updated clinical data on REP 2139-Ca based combination therapies in HBV infection and HBV / HDV co-infection at the 25th Annual Meeting of the Asia Pacific Association for the Study of the Liver to be held from February 20 -24, 2016 in Toyko, Japan. Three presentations on Replicor technology will be made during the meeting: read more

BiondVax Receives Additional Grant Approval

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the National Authority for Technological Innovation (NATI), formerly known as the Office of the Chief Scientist, agreed to fund up to 40% of a NIS 3.6 million (US$920,000) project towards ongoing development of the Company’s Universal Flu Vaccine.For more information, please visit http://www.biondvax.com.

Currently undergoing late Phase 2 clinical trials, BiondVax’s vaccine has shown significantly increased effectiveness against multiple seasonal and pandemic flu strains when compared to today’s existing flu vaccines.  With today’s grant approval, NATI has, since 2006, granted $5.5M to BiondVax. The non-dilutive grants are repayable from royalties generated from future sales of BiondVax’s vaccine, once available on the market.

Endo Announces Initiation of Phase 2B Clinical Trial of Collagenase Clostridium Histolyticum in Cellulite

PRNewswire/ — Endo International plc (NASDAQ: ENDP) (TSX: ENL) today announced the initiation of its Phase 2b study of collagenase clostridium histolyticum (or “CCH”) for the treatment of edematous fibrosclerotic panniculopathy (“EFP”), commonly known as cellulite. CCH is known in its currently approved indications in the U.S. as XIAFLEX®.

“Cellulite affects millions of U.S. women, dimpling their skin, impacting their appearance and causing bother and self-consciousness for many,” said Dr. Susan Hall, Executive Vice President, Chief Scientific Officer and Global Head of R&D and Quality at Endo. “There are no FDA-approved pharmacological options for cellulite and many currently available treatment options have not demonstrated a scientific benefit. We believe that if CCH is successful in clinical trials and if approved by the FDA, it could become the first office-based biological treatment option for cellulite that is supported by scientific results. Endo is looking forward to expanding the understanding of using CCH for this aesthetic indication.” read more

Regen BioPharma, Inc.’s Immune Checkpoint Inhibitor Found to Stimulate Key Immune System Proteins Interleukin-17 and Interleukin-18  

RegenBioPharma, Inc ., (OTCBB: RGBP) and (PINK: RGBP) announced today the filing of two patent applications covering new immunological pathways activated by gene silencing of the Company’s checkpoint inhibitor target NR2F6. The results, which are part of a collaborative effort with Dr. Santosh Kesari, demonstrate that suppression of NR2F6 in T cells results in increased expression of key immune stimulatory proteins interleukin-17 (IL-17) and interleukin-18 (IL-18). Dr. Santosh Kesari serves as the Professor of Neurosciences and Chair of the Department of Neuro-oncology and Neuro-Therapeutics at the John Wayne Cancer Institute (Providence Saint John’s Health Center).

 

Micreos Secures €12 Million for New Products Containing Staphefekt; Alternative to Antibiotics Can Help Millions

Dutch biotech company Micreos announces today that it has secured €12 million in additional equity for the global development of its antibacterial lysin technology, Staphefekt in new products. Micreos intends to use the secured funds, which run until 2017, for the global development of Staphefekt™ as a pharmaceutical (Rx) product. For more information about Micreos’ technology or for investor relations, visit http://www.micreos.com.

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.